NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered ...
From a distribution perspective, the B2C channel holds around 42.5% of market revenue in 2025, emerging as the dominant route ...
Driven by a dual product strategy of "digestion + gynecology," Wedge Pharma has established differentiated market barriers and is gradually building a product matrix that spans the entire lifecycle of ...
Biphenomycins, natural products derived from bacteria, show excellent antimicrobial activity, but have long remained out of ...
FDA's new guidance clarifies promotional practices for biosimilars, ensuring accurate marketing and preventing misleading ...
Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and ...
From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.
Biological communities are rarely stable. Their composition is constantly changing, depending on the environmental conditions in the respective ecosystems—and sometimes this change is so vast that ...
The term Secure Product Development Framework (SPDF) was introduced by FDA in the draft guidance "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions" ...
A Cape Girardeau medical business is expanding, growing its presence in the city and across the Midwest. Cardinal Biologicals Inc. at 821 Progress St. plans to create a lab consumables production line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback